Abstract | BACKGROUND: METHODS: RESULTS: During the preprophylaxis period, 62 children with ALL and 24 children with AML experienced a total of 44 episodes of bloodstream infection and 22 episodes of IFI. Seven patients died of severe infection. In contrast, in the prophylaxis period, 10 episodes of bloodstream infection occurred and no IFIs were reported to occur in 51 patients with ALL and 14 patients with AML. Moreover, no patient died of severe infection. Episodes of febrile neutropenia and intensive care unit stay were significantly reduced during the prophylaxis period. CONCLUSIONS:
|
Authors | Ting-Chi Yeh, Hsi-Che Liu, Jen-Yin Hou, Kuan-Hao Chen, Ting-Huan Huang, Ching-Yi Chang, Der-Cherng Liang |
Journal | Cancer
(Cancer)
Vol. 120
Issue 8
Pg. 1255-62
(Apr 15 2014)
ISSN: 1097-0142 [Electronic] United States |
PMID | 24415457
(Publication Type: Journal Article)
|
Copyright | © 2013 American Cancer Society. |
Chemical References |
- Antifungal Agents
- Antineoplastic Agents
- Echinocandins
- Lipopeptides
- Pyrimidines
- Triazoles
- Ciprofloxacin
- Voriconazole
- Micafungin
|
Topics |
- Adolescent
- Antibiotic Prophylaxis
- Antifungal Agents
(therapeutic use)
- Antineoplastic Agents
(adverse effects)
- Child
- Child, Preschool
- Ciprofloxacin
(therapeutic use)
- Cohort Studies
- Drug Costs
- Echinocandins
(therapeutic use)
- Female
- Humans
- Infant
- Leukemia, Myeloid, Acute
(drug therapy)
- Lipopeptides
(therapeutic use)
- Male
- Micafungin
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy)
- Pyrimidines
(therapeutic use)
- Sepsis
(prevention & control)
- Triazoles
(therapeutic use)
- Voriconazole
|